Montara Therapeutics closes $20 million funding

14 March 2025

US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing.

The company noted that the financing round, which brings Montara’s total seed funding to $28 million, includes increased participation from all existing investors, including founding investor SV Health Investors’ Dementia Discovery Fund, Two Bear Capital, Dolby Family Ventures, and KdT Ventures, along with new investments from BEVC and additional investors.

“As we take this next critical step towards the clinic, we’re thrilled by upsized commitments from our existing investors and welcome the new investors to our syndicate,” said Nicholas Hertz, founder and chief executive of Montara.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology